Major pharma firms like Eli Lilly, GSK, Merck, Regeneron and Sanofi announce $35B+ in share buybacks since December, ...

Inventiva is trimming its pipeline and enacting layoffs in an effort to get its lead MASH drug approved, the company ...

Leaked Pfizer Phase 1 trial shows mevrometostat plus Xtandi reduced prostate cancer progression risk by 49%. Data sparked ...

Novartis acquires Anthos' abelacimab for $925M upfront and up to $3.1B total, marking CEO Bill Meury's second major exit and ...

Novo Nordisk hit back at telehealth company Hims’ controversial Super Bowl commercial touting cheaper versions of brand-name ...

Eli Lilly is betting up to $630 million on an experimental MASH treatment from a South Korean biotech. The pharma giant ...

Vertex chief operating officer Stuart Arbuckle plans to retire in July, the company announced Monday afternoon. He will be ...

Twenty-two state attorneys general sued the Trump administration on Monday in a bid to halt a new cap on indirect costs for ...

Several brand-name drugmakers believe they will withstand any drug pricing impacts from President Donald Trump’s tariffs — ...

Boehringer Ingelheim said its experimental treatment for a chronic lung disease succeeded in a pivotal study, and it's taking ...

Roche's $8 billion InterMune acquisition, disclosed a decade ago, is now being handed to a specialty pharmaceutical company.

German pharma company Merck KGaA confirmed that it is in talks to acquire SpringWorks Therapeutics, though a deal has yet to be announced.